JP Morgan is always happy to be a lone voice in the wilderness. Mayne Pharma is one stock the analysts feel the market has completely misinterpreted.
When brokers start ceasing coverage of a stock when they can’t find anything good to say, experience suggests the administrators are not too far away.
Beware the broker trap. If a stock is rated a Buy, and its price falls, does that make it even more of a Buy? Or is something wrong? Oops, mea culpa.
Citigroup sees a lot of upside for Commander over the next few years, if management gets it right.
The Pommy love affair with Aussie wine appears to be over. When there’s so much of the stuff in the bargain bin, it can only be deemed to be on the nose. Foster’s should be very concerned.
Atlantic salmon sales in Australia have taken off, and Merrill Lynch is suggesting investors should get on board the healthy revolution.
Resource Capital Research forecasts a steadily climbing spot price for uranium, but not every man and his dog will automatically benefit from this.
Most securities analysts seem to be happy with the proposed tie-in between OneSteel and Smorgon, but not Credit Suisse.
Although the next CPI figure will likely be a doozy, CommBank does not believe the fundamentals justify another Australian interest rate hike.
Blame Pacifica. Blame Ion. Fact is investors are not giving management at CMI any credit, says ABN Amro.